Results from a multi-country study presented at the American Society of Nephrology showed that treating hyperkalemia with AstraZeneca’s Lokelma and recommended therapy can improve outcomes for patients with chronic kidney disease or heart failure.
AstraZeneca has administrative, manufacturing, and logistics operations in northern Delaware.
Anjay Rastogi, M.D., Ph.D., clinical chief of Nephrology at UCLA Health, said: “Evolving science shows that proactive management of hyperkalemia with a potassium binder allows guideline recommended RAASi therapy to be maintained at the optimized dose levels to improve outcomes for patients with CKD or heart failure. Yet, real-world evidence provides a sharp reality check of what’s actually happening to cardiorenal patients following an episode of hyperkalemia in clinical practice and the serious consequences down-titration and discontinuation of RAASi therapy can have, leading to poorer outcomes and increased mortality.”
Ruud Dobber, executive vice president of BioPharmaceuticals Business Unit, AstraZeneca, said: “Lokelma can be a pivotal therapeutic strategy to address this urgent disease burden. At AstraZeneca, we remain committed to working with the cardiorenal community to enable guideline-recommended RAASi therapy and achieve more effective cardiorenal protection for patients.”
Lokelma is indicated for the treatment of HK in adults It is a sodium zirconium silicate, formulated as a powder for oral suspension, that acts as a potassium-removing medicine. It is administered orally. Lokelma has been approved in more than 50 countries, including the US, EU and Japan.
